BMN 351

DRUG2 trials

Sponsors

BioMarin Pharmaceutical

Conditions

Duchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD)

Phase 1

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy

Active, not recruitingNCT06280209

BioMarin PharmaceuticalDuchenne Muscular Dystrophy

Start: 2024-01-03End: 2027-04-14Updated: 2026-06-25

Phase 2

An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy

Enrolling by invitationNCT07573631

BioMarin PharmaceuticalDuchenne Muscular Dystrophy (DMD)

Start: 2026-04-20End: 2031-12-01Target: 18Updated: 2026-07-24